Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 57-66

  McHutchison, John G ^a   Poynard, Thierry ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Serv d'HepatoGastroenterologie   (France)

Author keywords

Chronic hepatitis C; Interferon; Naive; Ribavirin

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FIBROSIS; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032896077     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312
2. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23:8-12
3. Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-86
4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
5. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432
6. Schalm SW, Hansen BE, Chemello L. et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966
7. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-1645
8. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitic C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74(pt 6):1093-1102
9. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293
11. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe HEA, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998;28:960-964
12. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis [published erratum appears in N Engl J Med 1996;334:1143]. N Engl J Med 1995;332:1457-1462
13. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903
14. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598
15. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477
16. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881
17. Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28(suppl 4 pt 2):1121-1127